480 ARSENAL WAY, SUITE 100, WATERTOWN, MA
Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Acrivon Therapeutics Approves Amended 2022 Equity Incentive Plan
Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Termination of OncoSignature Diagnostic Agreement with Akoya Biosciences
Investor Presentation
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload